Ali Khadim

Mr. Ali Khadim

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2024 in Circulation Research
Verified
Journal Article
Closed access
XCXuran Chu
Xuran Chu
VKVahid Kheirollahi
Vahid Kheirollahi
ALArun Lingampally
Arun Lingampally
PCPrakash Chelladurai
Prakash Chelladurai
CVChanil Valasarajan
Chanil Valasarajan
SBSaverio Bellusci
Saverio Bellusci
BACKGROUND: The precise origin of newly formed ACTA2+ (alpha smooth muscle actin-positive) cells appearing in nonmuscularized vessels in the context of pulmonary hypertension is still debatable although it is believed that they predominantly derive from preexisting vascular smooth muscle cells (VSMCs). METHODS: Gli1 Cre-ERT2 ; tdTomato flox mice were used to lineage trace GLI1+ (glioma-associated oncogene homolog 1-positive) cells in the context of pulmonary hypertension using 2 independent models of vascular remodeling and reverse remodeling: hypoxia and cigarette smoke exposure. Hemodynamic measurements, right ventricular hypertrophy assessment, flow cytometry, and histological analysis of thick lung sections followed by state-of-the-art 3-dimensional reconstruction and quantification using Imaris software were used to investigate the contribution of GLI1+ cells to neomuscularization of the pulmonary vasculature. RESULTS: The data show that GLI1+ cells are abundant around distal, nonmuscularized vessels during steady state, and this lineage contributes to around 50% of newly formed ACTA2+ cells around these normally nonmuscularized vessels. During reverse remodeling, cells derived from the GLI1+ lineage are largely cleared in parallel to the reversal of muscularization. Partial ablation of GLI1+ cells greatly prevented vascular remodeling in response to hypoxia and attenuated the increase in right ventricular systolic pressure and right heart hypertrophy. Single-cell RNA sequencing on sorted lineage-labeled GLI1+ cells revealed an Acta2 high fraction of cells with pathways in cancer and MAPK (mitogen-activated protein kinase) signaling as potential players in reprogramming these cells during vascular remodeling. Analysis of human lung-derived material suggests that GLI1 signaling is overactivated in both group 1 and group 3 pulmonary hypertension and can promote proliferation and myogenic differentiation. CONCLUSIONS: Our data highlight GLI1+ cells as an alternative cellular source of VSMCs in pulmonary hypertension and suggest that these cells and the associated signaling pathways represent an important therapeutic target for further studies.

11 January 2022 in Cells
Verified
Journal Article
Open access
PDF file
RWRoxana Wasnick
Roxana Wasnick
ISIrina Shalashova
Irina Shalashova
JWJochen Wilhelm
Jochen Wilhelm
AKAli Khadim
Ali Khadim
NSNicolai Schmidt
Nicolai Schmidt
AGAndreas Günther
Andreas Günther
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal degenerative lung disease of unknown etiology. Although in its final stages it implicates, in a reactive manner, all lung cell types, the initial damage involves the alveolar epithelial compartment, in particular the alveolar epithelial type 2 cells (AEC2s). AEC2s serve dual progenitor and surfactant secreting functions, both of which are deeply impacted in IPF. Thus, we hypothesize that the size of the surfactant processing compartment, as measured by LysoTracker incorporation, allows the identification of different epithelial states in the IPF lung. Flow cytometry analysis of epithelial LysoTracker incorporation delineates two populations (Lysohigh and Lysolow) of AEC2s that behave in a compensatory manner during bleomycin injury and in the donor/IPF lung. Employing flow cytometry and transcriptomic analysis of cells isolated from donor and IPF lungs, we demonstrate that the Lysohigh population expresses all classical AEC2 markers and is drastically diminished in IPF. The Lysolow population, which is increased in proportion in IPF, co-expressed AEC2 and basal cell markers, resembling the phenotype of the previously identified intermediate AEC2 population in the IPF lung. In that regard, we provide an in-depth flow-cytometry characterization of LysoTracker uptake, HTII-280, proSP-C, mature SP-B, NGFR, KRT5, and CD24 expression in human lung epithelial cells. Combining functional analysis with extracellular and intracellular marker expression and transcriptomic analysis, we advance the current understanding of epithelial cell behavior and fate in lung fibrosis.

20 June 2022 in Cells
Verified
Journal Article
Open access
PDF file
VKVahid Kheirollahi
Vahid Kheirollahi
AKAli Khadim
Ali Khadim
GKGeorgios Kiliaris
Georgios Kiliaris
MKMartina Korfei
Martina Korfei
MBMargarida Maria Barroso
Margarida Maria Barroso
EAElie El Agha
Elie El Agha
Insulin-like growth factor (IGF) signaling controls the development and growth of many organs, including the lung. Loss of function of Igf1 or its receptor Igf1r impairs lung development and leads to neonatal respiratory distress in mice. Although many components of the IGF signaling pathway have shown to be dysregulated in idiopathic pulmonary fibrosis (IPF), the expression pattern of such components in different cellular compartments of the developing and/or fibrotic lung has been elusive. In this study, we provide a comprehensive transcriptional profile for such signaling components during embryonic lung development in mice, bleomycin-induced pulmonary fibrosis in mice and in human IPF lung explants. During late gestation, we found that Igf1 is upregulated in parallel to Igf1r downregulation in the lung mesenchyme. Lung tissues derived from bleomycin-treated mice and explanted IPF lungs revealed upregulation of IGF1 in parallel to downregulation of IGF1R, in addition to upregulation of several IGF binding proteins (IGFBPs) in lung fibrosis. Finally, treatment of IPF lung fibroblasts with recombinant IGF1 led to myogenic differentiation. Our data serve as a resource for the transcriptional profile of IGF signaling components and warrant further research on the involvement of this pathway in both lung development and pulmonary disease.

8 May 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
MZMahsa Zabihi
Mahsa Zabihi
AKAli Khadim
Ali Khadim
ALArun Lingampally
Arun Lingampally
AVAna Ivonne Vazquez-Armendariz
Ana Ivonne Vazquez-Armendariz
SHStefan Hadzic
Stefan Hadzic
EAElie El Agha
Elie El Agha
Idiopathic pulmonary fibrosis is the most common and aggressive form of interstitial lung disease. Despite extensive research on the pathomechanisms of fibrogenesis, little is known about the mechanisms of fibrosis resolution. Here, lineage tracing of alveolar fibroblasts was carried out during fibrosis development and delayed resolution in aged mice. Histological analyses, single-cell transcriptomics, and ex vivo models including alveolar organoids and precision-cut lung slice cultures were employed. The data reveal that lipofibroblasts contribute to myofibroblast formation during fibrogenesis, with the reverse differentiation trajectory occurring during fibrosis resolution. Importantly, delayed resolution is associated with the persistence of ADAM metallopeptidase with thrombospondin type 1 motif 4-positive (ADAMTS4+) cells. Investigation of human lung transplant tissues, single-cell and spatial transcriptomic datasets, and functional ex vivo interventions reveal strong clinical relevance. Our study underscores the significance of the lipofibroblast-to-myofibroblast reversible switch in fibrosis development and resolution and identifies ADAM metallopeptidase with thrombospondin type 1 motif 4 as a potential therapeutic target in human lung fibrosis.

6 January 2026 in JCI Insight
Verified
Journal Article
Open access
PDF file
RWRene Weyer
Rene Weyer
KVKatharina Völker
Katharina Völker
TPTamara Potapenko
Tamara Potapenko
LKLisa Krebes
Lisa Krebes
MAMarco Abesser
Marco Abesser
Swati DabralSwati Dabral
Swati Dabral
Activation of lung fibroblasts in response to epithelial injury and inflammation provokes pulmonary fibrosis (PF). Endogenous molecular brakes counteracting fibroblast activity can be targets for therapies. Preclinical studies of synthetic C-type natriuretic peptide (CNP) indicated that this hormone might provide such a brake. As shown here, CNP exerts antifibrotic effects in cultured lung fibroblasts as well as in precision cut lung slices from patients with PF, supporting clinical relevance. Therefore, augmenting or supplementing endogenous CNP could improve the treatment of such patients. To unravel whether paracrine CNP counteracts inflammation-driven PF, we studied mice with fibroblast-restricted KO of guanylyl-cyclase-B (GC-B), its cGMP-synthesizing receptor. Fibroblast GC-B-KO mice had enhanced bleomycin-induced lung inflammation, with increased expression of proinflammatory, profibrotic cytokines. Nevertheless, subsequent PF was not exacerbated. Molecular studies revealed that inflammation led to inhibition of CNP signaling in resident myofibroblasts, namely GC-B downregulation and induction of CNP/cGMP-degrading pathways. Despite this, a single s.c. injection of the recently developed long-acting CNP analog, MS~[Gln 6,14 ]CNP-38, abrogated experimental lung inflammation and fibrosis. We conclude that CNP signaling in lung fibroblasts has antiinflammatory and antifibrotic effects. Attenuation of this endogenous brake participates in the pathogenesis of PF, and rescuing this pathway with long-acting CNP-analogs may have therapeutic potential.

19 August 2025 in STAR Protocols
Verified
Journal Article
Open access
AKAli Khadim
Ali Khadim
MFMahtab Shahriari Felordi
Mahtab Shahriari Felordi
HHHawlader Sabbir Hasan
Hawlader Sabbir Hasan
GKGeorgios Kiliaris
Georgios Kiliaris
MZMahsa Zabihi
Mahsa Zabihi
EAElie El Agha
Elie El Agha
Precision-cut lung slices (PCLSs) largely preserve the native structural and cellular complexity of the lung, enabling detailed spatial analysis of resident cell populations. Here, we present a protocol for generating PCLSs from mouse lungs for subsequent immunofluorescent staining to detect protein expression. We describe steps for preparing animals and instruments and generating PCLSs. We then detail procedures for immunofluorescence for ACTA2 while preserving the endogenous fluorescent reporter in PCLSs and co-staining ACTA2 and MKI-67 with the endogenous reporter in PCLSs. For complete details on the use and execution of this protocol, please refer to Khadim et al.1.